Want to see OGEN full AI Analyst Report?
OGEN Stock Chart & Stats
$0.72
-$0.04(-10.69%)
At close: 4:00 PM EST
$0.72
-$0.04(-10.69%)
Day’s Range― - ―
52-Week Range$0.50 - $1.58
Previous CloseN/A
Volume445.36K
Average Volume (3M)211.78K
Market Cap
$2.64M
Enterprise Value-$3.30M
Total Cash (Recent Filing)$6.11M
Total Debt (Recent Filing)$56.13K
Price to Earnings (P/E)―
Beta1.97
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,511,957
10 Day Avg. Volume326,842
30 Day Avg. Volume211,777
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.20
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-1.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.53
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Leadership ChangeThe appointment of Janet Huffman as CEO and CFO may bring strategic leadership and operational improvements, potentially enhancing the company's focus on financial restructuring and growth.
Strategic PartnershipsOragenics' focus on R&D collaborations and strategic partnerships can drive innovation and provide financial support, aiding in the development and commercialization of its proprietary products.
Lantibiotic PlatformThe proprietary lantibiotic platform positions Oragenics to address antibiotic resistance, offering a competitive advantage in developing novel antibiotics with unique mechanisms of action.
Bears Say
Financial DistressOngoing financial distress, characterized by persistent losses and negative equity, threatens long-term viability and limits the company's ability to invest in growth opportunities.
Negative Cash FlowConsistently negative operating cash flow indicates challenges in generating sufficient cash to cover operational expenses, potentially impacting future growth and sustainability.
Declining RevenuesDeclining revenues highlight difficulties in product commercialization and market penetration, which are critical for achieving financial stability and growth.
Oragenics News
OGEN FAQ
What was Oragenics Inc’s price range in the past 12 months?
Oragenics Inc lowest stock price was $0.50 and its highest was $1.58 in the past 12 months.
What is Oragenics Inc’s market cap?
Oragenics Inc’s market cap is $2.64M.
When is Oragenics Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Oragenics Inc’s earnings last quarter?
Currently, no data Available
Is Oragenics Inc overvalued?
According to Wall Street analysts Oragenics Inc’s price is currently Overvalued.
Does Oragenics Inc pay dividends?
Oragenics Inc does not currently pay dividends.
What is Oragenics Inc’s EPS estimate?
Oragenics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oragenics Inc have?
Oragenics Inc has 4,511,957 shares outstanding.
What happened to Oragenics Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Oragenics Inc?
Currently, no hedge funds are holding shares in OGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oragenics Inc
Oragenics, Inc. (OGEN) is a U.S.-based biotechnology firm primarily focused on creating treatments for infectious diseases. Among its pipeline assets are two vaccine candidates designed to combat the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2): NT-CoV2-1, an intranasal formulation, and Terra CoV-2, an intramuscular option. Beyond its infectious disease focus, Oragenics also has other experimental treatments under development, including LPT3-04, targeting weight loss, and SMaRT Replacement Therapy, a topical solution aimed at preventing dental cavities. Strategic alliances are also a part of its operations. This includes a licensing deal with Noachis Terra Inc. for patents and biological resources related to pre-fusion coronavirus spike proteins. Additionally, Oragenics is collaborating with Precigen, Inc. and ILH Holdings, Inc. on the advancement and market introduction of MU1140 and its associated compounds. Established in 1996, the company, formerly known as Oragen, Inc., maintains its headquarters in Tampa, Florida.
Technical Analysis
Ownership Overview
3.37% Insiders
0.87% Mutual Funds
0.05% Other Institutional Investors
95.71% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---